Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer

Status: Completed

Conditions: Bacterial Infections

Treatments: Drug: Azithromycin SR

Study type: Observational

Funder types: Industry

Identifiers

NCT00998309

A0661202

Details and patient eligibility

About

To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.

Full description

All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.

Enrollment: 502 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subjects diagnosed with skin and soft tissue infection, sexually-transmitted infection, and infection of the oral.
• Subjects must have no prior experience with Azithromycin SR.

Exclusion criteria

• Patients not administered Azithromycin SR.

Trial design

502 participants in 1 patient group

Azithromycin SR

Description:

Patients taking Azithromycin.

Treatment:

Drug: Azithromycin SR